MAPT and Alzheimer disease: Due to the strong and growing body of evidence that blood-based biomarkers such as Aβ42/40, ptau181, ptau217 and ptau231 are powerful in discriminating healthy ageing from AD [40–42], the necessity for expensive amyloid-PET scans in tau-targeting clinical trials is questionable.